Active	Status	Sponsor type	Region	Phase	Filter
12 Active 0 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sommerville, Fay
ELEVAATE, NCT05856331: Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Recruiting	2	90	Europe, US, RoW	INBRX-101, Zemaira	Inhibrx Biosciences, Inc	Alpha 1-Antitrypsin Deficiency, Emphysema	05/25	06/25
NCT05292950 / 2022-003467-21: Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease	Recruiting	1	104	Europe, RoW	ARO-MUC5AC, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma, Chronic Obstructive Pulmonary Disease	11/24	11/24
NCT05276570 / 2022-003466-20: Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease	Recruiting	1	149	Europe, RoW	ARO-RAGE, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma	12/24	02/25
Olejniczak, Anna
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria	Active, not recruiting	2	208	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics	Chronic Spontaneous Urticaria	09/23	03/25
NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria	Active, not recruiting	2	196	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics, Celldex Therapeutics, Inc.	Chronic Inducible Urticaria	06/24	10/24
NCT05292950 / 2022-003467-21: Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease	Recruiting	1	104	Europe, RoW	ARO-MUC5AC, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma, Chronic Obstructive Pulmonary Disease	11/24	11/24
NCT05276570 / 2022-003466-20: Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease	Recruiting	1	149	Europe, RoW	ARO-RAGE, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma	12/24	02/25
Stowers, Taisha
NCT05537025: Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis Oct 2023 - Dec 2023 : Data from trial for IPF	Recruiting	1/2	97	Europe, RoW	ARO-MMP7 Inhalation Solution, Placebo	Arrowhead Pharmaceuticals	Idiopathic Pulmonary Fibrosis	03/25	03/25
NCT05292950 / 2022-003467-21: Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease	Recruiting	1	104	Europe, RoW	ARO-MUC5AC, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma, Chronic Obstructive Pulmonary Disease	11/24	11/24
NCT05276570 / 2022-003466-20: Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease	Recruiting	1	149	Europe, RoW	ARO-RAGE, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma	12/24	02/25
Kobielsz-Gembala, Iwona
NCT05292950 / 2022-003467-21: Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease	Recruiting	1	104	Europe, RoW	ARO-MUC5AC, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma, Chronic Obstructive Pulmonary Disease	11/24	11/24
NCT05276570 / 2022-003466-20: Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease	Recruiting	1	149	Europe, RoW	ARO-RAGE, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma	12/24	02/25